Abbreviated name: ET-1
Compound class:
Endogenous peptide in human, mouse or rat
Comment: Endothelin-1 (ET-1) is a 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production (for reviews see [2] and [3] ). As peptides defined by SMILES strings PubChem contains a number of alternative CIDs either with the name "Endothelin-1" and/or Mw 2491.914. Our choice of PubChem CID 16212950 reflects the majority of sources submitting substance structures and assay data.
COVID-19: The level of ET-1 in plasma from COVID-19 patients positively correlates with clinical severity of illness [1]. This finding suggests that endothelin receptor antagonists may provide a therapeutic option for some COVID-19 patients.
Species: Human, Mouse, Rat
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: endothelin, et-1 |
|
References |
1. Abraham GR, Kuc RE, Althage M, Greasley PJ, Ambery P, Maguire JJ, Wilkinson IB, Hoole SP, Cheriyan J, Davenport AP. (2022)
Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. J Mol Cell Cardiol, 167: 92-96. [PMID:35339512] |
2. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. (2016)
Endothelin. Pharmacol Rev, 68 (2): 357-418. [PMID:26956245] |
3. Davenport AP, Kuc RE, Southan C, Maguire JJ. (2018)
New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine. Physiol Res, 67 (Supplementum 1): S37-S54. [PMID:29947527] |
4. Maguire JJ, Davenport AP. (1995)
ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol, 115 (1): 191-7. [PMID:7647976] |
5. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. (1990)
Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature, 348 (6303): 732-5. [PMID:2175397] |